Rosuvastatin and atorvastatin: Comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 5, Issue , 2012, Pages 13-30

  Abbas, Ahmed ^a   Milles, John ^b   Ramachandran, Sudarshan ^b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

Atorvastatin; New onset diabetes; Rosuvastatin; Statins; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PRAVASTATIN; PROTEIN KINASE C; ROSUVASTATIN; SIMVASTATIN; SOMATOMEDIN BINDING PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE;

ACUTE CORONARY SYNDROME; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIPOLYSIS; LIVER DISEASE; MARKER GENE; MORTALITY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET ALPHA CELL; PATHOGENESIS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SLCO1B1 GENE; STROKE;

EID: 84857885775     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S7591     Document Type: Review

References (131)

1. Virchow R. Phlogose und thrombose in getissystem, gesanmelte unhan- dlungen zur wissensehaftlichen medlein. Frankfurt-am-Main, Germany: Meidinger Sohn; 1856:458.
2. Mendis S. The contribution of the Framingham Heart Study to the preven- tion of cardiovascular disease: a global perspective. Prog Cardiovasc Dis. 2010;53:10-4.
3. Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in non smokers. Circulation. 1997;96:2128-36.
4. Scarborough P, Bhatnager P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary Heart Disease Statistics. 2010.
5. Griffiths C, Brock A. Twentieth century mortality trends in England and Wales. Health Stat Q. 2003;5-17
6. Hotchkiss JW, Davies C, Gray L, Bromley C, Capewell S, Leyland AH. Trends in adult cardiovascular disease risk factors and their socio-economic patterning in the Scottish population 1995-2008: cross-sectional surveys. BMJ Open. 2011 doi:10.1136/bmjopen-2011-000176.
7. Wilson A, Siskind V. Coronary heart disease mortality in Australia: is mortality starting to increase among young men? Int J Epidemiol. 1995;24:678-84.
8. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50:2128-32.
9. Schachter M. Chemical, pharmacokinetic and pharmaco dynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117-25.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of Coronary Heart {Eth}isease with Pravastatin in Men with Hypercholesterolemia. N Engl J Med. 1995;333:1301-8.
12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
13. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
17. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
18. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
19. Trusler D. Statin prescriptions in UK now total a million each week. BMJ. 2011;343:d4350.
20. International Diabetes Federation. Diabetes atlas. 4th edition. Brussels: International Diabetes Federation (IDF); 2009. Available at http://www.idf.org/diabetesatlas/executive-summary (accessed on 22/10/2011).
21. Grarup N, Anderson G. Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism. Curr Opin Clin Nutr Metab Care. 2007;10:420-6.
22. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002 (Suppl 6A); 113:3S-11.
23. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and treatment. Lancet. 2008;371:2153-6.
24. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103: 357-62.
25. National Institute for Health and Clinical Excellence. Lipid modification Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: NICE, 2008 (reissued 2010).
26. National Institute for Health and Clinical Excellence. Type 2 diabetes. The management of type 2 diabetes. NICE clinical guideline. London: NICE, 2008.
27. Buse J. Statin Treatment in Diabetes Mellitus. Clinical Diabetes. 2003;21: 168-72.
28. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-57.
29. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev. 2003;2:332-8.
30. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413-8.
31. Joint Formulary Committee. British National Formulary. 62nd ed. London: BMJ. Group and Pharmaceutical Press; 2011.
32. Gaw A, Packard CJ, Shepherd J. (Editors), Statins. The HMG CoA reductase inhibitors in perspective, Martin Dunitz, London, 2000, pp. 49-61.
33. McTavish D, Sorkin EM. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991;42:65-89.
34. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28B-32.
35. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160-4.
36. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. Jul 1996;36(7):604-9.
37. Warwick MJ, Dane AL, Raza A, Schneck DW. Single and multiple-dose pharmacokinetics and safety of the new HMGCoA reductase inhibitor ZD4522. Atherosclerosis. 2000;151:39.
38. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med. 2000;160:2273-80.
39. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-60.
40. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res. 2010;51:1546-53.
41. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-93.
42. Kandoussi A, Martin F, Hazzan M, et al. HMG-CoA reductase inhibition and PPAR-alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin Sci (Lond). 2002;103 Suppl 48:81S-3.
43. Armani A, Toth PP. The CARDS trial: diabetic patients dealt a winning hand. Curr Atheroscler Rep. 2006;8:429-32.
44. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-45.
45. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355: 549-9.
46. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291: 1071-80.
47. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297: 1344-53.
48. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-65.
49. Belalcazar LM, Raghavan VA, Ballantyne CM. Statin-induced diabetes: will it change clinical practice? Diabetes Care. 2009;32:1941-3.
50. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375: 735-42.
51. Shepherd J, Blauw GJ, Murphy MB, et al: PROSPER study group. PROspective Study of Pravastatin in Elderly at Risk. Lancet. 2002;360: 1623-30.
52. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.
53. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-9.
54. Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower that average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT = LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149-58.
55. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24:1359-62.
56. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a metaanalysis. Diabetes Care. 2009;32:1924-9.
57. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57:1535-45.
58. Priess D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared to moderate = dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-64.
59. de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2002;292:1307-6.
60. Armitage J, Bowman L, Wallendszus K, et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2011;376:1658-69.
61. Walker E, Hernandez AV, Kattan MW. Meta-analysis: Its strengths and limitations. Cleve Clin J Med. 2008;75:431-9.
62. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010;1:36-47.
63. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
64. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2010;91:258S-61.
65. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-5.
66. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2003;27:88-94.
67. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98-107.
68. Stalenhoef AF, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005;26:2664-72.
69. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009;204:483-90.
70. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis. 2011;215:1-8.
71. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis. 2008;196:114-21.
72. Ding PY, Hsu P, Lu T. Statin Therapy on Insulin Resistance and Plasma Level of Adiponectin in Non-Diabetic, Hypercholesterolemic Patients. Acta Cardiol Sin. 2009;25:183-9.
73. Thongtang N, Ai M, Otokozawa S, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107:387-92.
74. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009;63:1308-13.
75. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003;46:1029-45.
76. MacDonald PE, Ha XF, Wang J, et al. Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion. Mol Endocrinol. 2001;15:1423-35.
77. Rorsman P, Eliasson L, Renström E, Gromada J, Barg S, Göpel S. The Cell Physiology of Biphasic Insulin Secretion. News Physiol Sci. 2000;15: 72-7.
78. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell. 2007;99:129-40.
79. Xia F, Gao X, Kwan E, et al. Disruption of pancreatic-cell lipid rafts modifies Kv2.1 channel gating and insulin exocytosis. J Biol Chem. 2004;279:24685-91.
80. Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology. 2008;149:5136-45.
81. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J. 1993;295:31-40.
82. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb. 2006;13:329-5.
83. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006;29:703-12.
84. Rizzo M, Spinas GA, Rini GB, Berneis K. Is diabetes the cost to pay for a greater cardiovascular prevention? Int J Cardiol. 2010;144:309-10.
85. Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther. 2008;83:731-9.
86. Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 2002;45:1475-83.
87. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49:1881-92.
88. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-10.
89. Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278:18368-75.
90. Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest. 2008;118:403-8.
91. Rütti S, Ehses JA, Sibler RA, et al. Lowand high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 2009;150:4521-30.
92. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. {Eth}istinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes. 2001;50:69-76.
93. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes. 2003;52:726-33.
94. Qian L, Xu L, Lin Y, Peng Y. Statins and beta-cell function. Med Sci Monit. 2010;16:1-2.
95. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291:C1208-12.
96. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab. 1995;80:836-40.
97. Böhm M, Herrmann W, Wassmann S, Laufs U, Nickenig G. Does statin therapy influence steroid hormone synthesis? Z Kardiol. 2004;93:43-8.
98. Zeggini E, Weedon MN, Lindgren CM, et al; Wellcome Trust Case Control Consortium (WTCCC), McCarthy MI, Hattersley AT. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336-41.
99. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220-32.
100. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772-9.
101. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83:687-700.
102. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
103. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761-70.
104. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol. 2006;97:6C-26.
105. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35:139-51.
106. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57:525-8.
107. Gotto JAM. Statins, cardiovascular disease, and drug safety. Am J Cardiol. 2006;97:3C-5.
108. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80: 565-81.
109. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-90.
110. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15:444-53.
111. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol. 2007;18:409-14.
112. Kivistö KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res. 2007;24:239-47.
113. Link E, Parish S, Armitage J, et al. SEARCH Collaborative Group, SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-99.
114. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726-33.
115. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330-41.
116. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81:650-3.
117. Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60-8.
118. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18 Suppl:S137-44.
119. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61:889-92.
120. Lenaz G, Bovina C, D'Aurelio M, et al. Role of mitochondria in oxidative stress and aging. Ann NY Acad Sci. 2002;959:199-213.
121. Papucci L, Schiavone N, Witort E, et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem. 2003;278:28220-8.
122. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30:669-75.
123. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-82.
124. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. N Z Med J. 1991;104:493-5.
125. Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58:1333-7.
126. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther. 1991;50:730-7.
127. Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf. 2009;32:591-7.
128. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97:229-35.
129. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91 Suppl 5:v1-52.
130. Reiner Z, Catapano AL, De Backer G, et al. European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-10 and 2010-2 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
131. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35.